HONG KONG – With the U.S. approval under its belt, Verastem Inc. is looking at China as the next big market for Copiktra (duvelisib), inking an exclusive licensing deal with CSPC Pharmaceutical Group Ltd., of Shijiazhuang, China, in exchange for $15 million up front in deal for rights to develop and commercialize Copiktra for all oncology indications in China.